UW Medicine
HARBORVIEW MEDICAL CENTER

SCREENING GUIDELINES FOR EXTREMELY DRUG RESISTANT ORGANISMS (XDRO) AND *CANDIDA AURIS*

Department:	Infection Prevention & Control
Effective Date:	1/2015
Review/Revision Date:	9/2024 (revised)
Reviewer:	Infection Prevention & Control Committee

POLICY PURPOSE:

To identify, screen, and isolate high risk patient populations that may be colonized or infected with *Candida auris* or other extremely drug resistant organisms (XDRO) to prevent transmission to other hospitalized patients and healthcare workers.

DEFINITION:

***High Risk:**

1. Patients who have been hospitalized or have had dialysis internationally within the past 12 months – **High Risk International Admit.**
2. Admitted from a hospital or facility with known high risk organism outbreak, per IPC guidance – **High Risk**.
3. It is the discretion of the IPC department to add additional high-risk populations to these criteria based on epidemiological investigation and/or based on PHSKC or WA DOH recommendations and alerts. Consult your IPC department for guidance.

****Low Risk**:

1. Admitted from a Skilled Nursing Facility, Long Term Acute Care, or ventilator capable Skilled Nursing Facility (SNF/LTAC/vSNF), other Rehab Facility.
2. Patients who have been hospitalized or have had dialysis outside of Washington State within the past 12 months.
3. Patients who have lived outside of the United States within the past 12 months.
4. It is the discretion of the IPC department to add additional low-risk populations to these criteria based on epidemiological review.

XDRO: Extremely Drug Resistant Organisms: VRSA, Carbapenemase producing organism (CPO), Carbapenem resistant *Acinetobacter baumannii* (CRAB), and other pan resistant organisms.

POLICY:

1. Screen and isolate, as indicated based on risk per tables below. Modifications to this guidance below can be determined by HMC Administration and IPC Leadership based on patient safety and critical capacity considerations.

***High Risk International Admits** - Private Room, No Cohorting

Organism test	Swab Source	Precautions	Isolation Flag
Acinetobacter	Rectal	Contact Plus	R/O XDRO
Candida auris	Axilla/Groin	Contact Plus	R/O Candida Auris
CPO	Rectal	Contact Plus	R/O XDRO

***High Risk** - Private Room, No Cohorting

Organism test	Swab Source	Precautions	Isolation Flag
Candida auris	Axilla/Groin	Contact Plus	R/O Candida Auris

****Low Risk -** OK to Cohort

Organism test	Swab Source	Precautions	Isolation Flag
Candida auris	Axilla/Groin	Standard Precautions	No flag
1. *Candida auris* 2. CPO	1. Axilla/Groin 2. Rectal	Standard Precautions	No flag

2. Tests can be performed in the outpatient setting prior to elective admission.

3. Precautions will be discontinued when all surveillance and any other microbiological testing is completed, and the patient is determined to meet criteria for discontinuation of precautions.

4. **This guidance is based on epidemiological review and is subject to change per IPC discretion.**

5. Lab Notes:
   - *C. auris* labs are processed at UWM Labs.
   - *Acinetobacter* labs are processed at HMC lab.
   - CPO labs are sent to Public Health Laboratories (PHL) lab and not available on the weekends.
   - Infection Prevention will coordinate with units for testing processed at PHL.

APPENDIX

HMC PEC Risk Assessment

REVIEW / REVISION DATES

1/2015	4/2019	6/2019	10/2023	4/2024
9/2024				

APPROVED BY:

John Lynch, MD, MPH
Associate Medical Director
Infection Prevention & Control
Employee Health Services